HBI-8000 + paclitaxel + trastuzumab

This is a three-drug investigational combination therapy consisting of: - **HBI-8000**: an oral small molecule inhibitor of class I histone deacetylases (HDACs). It modulates gene expression and immune cell function in the tumor microenvironment, enhancing antitumor immunity and potentially sensitizing tumors to other therapies[4][1]. - **Paclitaxel**: a cytotoxic chemotherapeutic agent that stabilizes microtubules, inhibiting cell division and inducing apoptosis. Widely used in breast cancer and other solid tumors[6][10]. - **Trastuzumab**: a humanized monoclonal antibody targeting the HER2/neu receptor. It inhibits HER2-mediated signaling pathways, leading to reduced proliferation of HER2-overexpressing tumor cells[6][8]. The rationale for combining these agents is based on their complementary mechanisms—epigenetic modulation by HBI-8000 may enhance immune response or sensitize tumors to chemotherapy and targeted therapy; paclitaxel provides direct cytotoxicity; trastuzumab targets HER2-positive cancer cells. This specific triple regimen is under investigation primarily for advanced/metastatic breast cancer with HER2 overexpression but may be explored in other solid tumors.

Brand names

Farydak